Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6+
SponsorIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
About this trial
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Eligibility criteria
Qualifiers
Patients with AML diagnosis according to WHO2022 or ICC2022
Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
Participant or his/her legal representative is willing and able to give informed consent for participation in the study
Disqualifiers
Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.
Trial design
Treatments tested in this trial
- Registration into the STREAM platform
Treatment groups
4,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lead sponsor
Hospital Vall d'Hebron
Collaborator
Cyprus Institute of Neurology and Genetics
Collaborator
European LeukemiaNet
Collaborator
Fundacion Para La Investigacion Hospital La Fe
Collaborator
Ostedusche Hematology and Oncology Study Group
Collaborator
Ospedale Pediatrico Bambin Gesù
Collaborator
Czech Lymphoma Study Group
Collaborator
Charite University, Berlin, Germany
Collaborator
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Collaborator
University of Bologna
Collaborator
Hannover Medical School
Collaborator
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Collaborator
Toscana Life Sciences Sviluppo s.r.l.
Collaborator
Lithuanian University of Health Sciences
Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto
Collaborator
Time.Lex
Collaborator
Source ClinicalTrials.gov